Navigation Links
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Date:9/8/2010

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

About N6022 N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy subjects is designed to evaluate the safety, tolerability and pharmacokinetics of single, increasing intravenous dosages of N6022.  Data from this first-in-man trial will provide important safety, pharmacokinetic, and biomarker information on which to base the design of subsequent trials of N6022 as well as the development of reductase dosage forms suitable for chronic administration.

Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO), reducing the body's pool of GSNO.  In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects.   Similarly, in the gut GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR upregulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.  GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNORN30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, a s-nitrosothi
'/>"/>

SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
2. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Supreme Court of Israel Rules in Favor of Sun Pharma
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Pharmacy Franchise Owners Association Taps David Mayper as Executive Director
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
11. Reportlinker Adds US Pharmaceutical Packaging Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Securities lawyers at ... Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in ... Concerned SLXP investors are encouraged to contact attorney Hamilton ... The investigation focuses upon the shareholder value of the ... would receive only $158.00 per share in cash. At ...
(Date:2/27/2015)... 2015  Boston Scientific Corporation (NYSE: BSX ... Annual Healthcare Conference on March 10 in ... , executive vice president and chief financial officer, and ... participate in a 25-minute question and answer session regarding ... p.m. ET. Following a 5-minute break, a question and ...
(Date:2/27/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its first quarter ended December 31, ... December 31, 2014, revenue was $1,336,685. Operating expenses were ... $0.02 per share.  Covalon,s President and ... pleased with the significant progress we have made over ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... Banner Health and ... jointly announce Banner Health,s system-wide conversion to Masimo rainbow® SET ... Health hospital will be cared for using the most technologically ... "The decision to convert our entire hospital system ...
... 2, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 2Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 3Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 4Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 5Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation (Meso ... Symposium on Malignant Mesothelioma on Monday, March 2. The ... Bethesda in Bethesda, Maryland. The following award recipients will ... the mission to cure mesothelioma. , The Klaus Brauch ... Miriam Ratner. Miriam runs the Meso Foundation’s monthly spousal ...
(Date:2/28/2015)... 2015 Dr. Perry Patel , ... residents, recently announced a special offer for the Zoom!® ... option for new and established patients at his Pismo Beach ... bright, white smile, Dr. Patel and his staff are ... down from the regular price of $450. , Zoom! ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at Back2Basics Outdoor ... student obtaining her Masters degree in social work at ... psychoeducation on substance use for teens at the local ... her studies. , “Even though these students are young, ... the high school and junior high school level,” said ...
(Date:2/28/2015)... 28, 2015 The noted Friedman Dental ... they have officially relaunched their website. The new version ... it contains a new section about their team members. ... the full biographies of each Friedman Dental Group team ... website was designed to provide our patients with the ...
Breaking Medicine News(10 mins):Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2
... Oct. 4 New research from the,University of ... the New England Journal of Medicine today raises ... screening using a,CT scan of the abdomen. "Gastrointestinal ... advancing new frontiers in medicine.,While all of us ...
... Eight Percent of U.S. Health Research Spending Goes ... Public and private,sources in the U.S. invested ... to a new report by Research!America. That amount,represents ... U.S.,sources spent overall on health research in 2006., ...
... 2007 A group working at the Swiss Institute ... University of Pavia has discovered that telomeres, the repeated ... shorten every time a cell divides, also contain RNA. ... calls into question our understanding of how telomeres function, ...
... 4 Removing barriers to,laboratory results by providing ... today announced that it has released a,consumer selected ... launched consumer health platform. "Consumers come to ... information that allows them to better manage their ...
... In a departure from,current FDA and EPA ... women of childbearing age to increase their seafood,consumption, ... potent,neurotoxin and other contaminants commonly found in seafood., ... eat more fish without,mentioning the documented public health ...
... Law Offices of Howard G. Smith,announces that a ... shareholders who purchased the common stock of Micrus Endovascular,Corporation ... 12,2007 and September 17, 2007, inclusive (the "Class Period"). ... District Court for the,Southern District of Florida. The ...
Cached Medicine News:Health News:Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 2Health News:Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 3Health News:Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 4Health News:U.S. Invests $9.3 Billion in Research to Improve Health Globally 2Health News:New telomere discovery could help explain why cancer cells never stop dividing 2Health News:Physicians Wellness Network Announces Lab Testing Services for Consumers built on Microsoft HealthVault 2
... premium product for acne, XtremeClear, powered ... on a scalable multi-application platform. A ... acne, XtremeClear works fast, providing noticeable ... treatments. Uncompromising safety in each of ...
... SpaTouch was designed specifically to meet the varying ... is a simple to use, compact, dual application ... lucrative field of light based hair removal. SpaTouch ... is safe for use on nearly all face ...
... all of the benefits and functionality ... the additional feature of being able ... scanner for importing and storage of ... images. This additional feature allows for ...
Inquire...
Medicine Products: